Former Arranta Bio CEO David Stevens has joined CDMO Kindeva Drug Delivery as Chief Commercial Officer, the company said. Prior to Arranta, Stevens held a variety of roles at Albany Molecular Research, Aptuit, and Charles River Laboratories.
Kindeva (formerly 3M Drug Delivery Systems) merged with Meridian Medical Technologies in late 2022. The company’s recent moves to expand its OINDP capabilities include the acquisition of inhaled drug CRO iPharma Labs and investments in lines for manufacturing lower-GWP MDIs.
Stevens commented, “The Kindeva organization has a strong history of achievement, expertise, and the infrastructure to handle an extensive range of critical complex drug delivery challenges. I am excited to work with the incredible experts bringing many life-changing therapies and the highest-quality products to patients, and I am looking forward to leveraging my commercial, operational, and strategic background to enable continued success for our partners worldwide.”
Kindeva CEO Milton Boyer said, “David brings a breadth of industry experience and a depth of commercial expertise that is essential for driving Kindeva’s enhanced scope and scale. His role is vital to our continued success as a premier CDMO and, in turn, the success of our partners bringing a broad range of drug delivery solutions to market.”
Read the Kindeva Drug Delivery press release.
